CureVac N.V. (CVAC): Price and Financial Metrics
GET POWR RATINGS... FREE!
CVAC Stock Price Chart Interactive Chart >
CVAC Price/Volume Stats
| Current price | $13.87 | 52-week high | $76.22 |
| Prev. close | $13.94 | 52-week low | $12.90 |
| Day low | $13.72 | Volume | 482,373 |
| Day high | $14.15 | Avg. volume | 648,142 |
| 50-day MA | $16.29 | Dividend yield | N/A |
| 200-day MA | $27.76 | Market Cap | 2.60B |
CureVac N.V. (CVAC) Company Bio
CureVac BV is a clinical-stage biopharmaceutical Company developing tumour immunotherapy. It offers RNA optimization that encode functional proteins that replace defective or missing proteins using the cell’s intrinsic translation machinery. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.
Latest CVAC News From Around the Web
Below are the latest news stories about CureVac NV that investors may wish to consider to help them evaluate CVAC as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayWe've got another busy day of trading ahead of us so let's get right to it with the biggest pre-market stock movers for Wednesday! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe've got another busy day of trading ahead of us and we're starting with the biggest pre-market stock movers for Tuesday! |
CureVac (CVAC) Begins Influenza Shot Dosing in Phase I StudyCureVac (CVAC) doses the first patient in a phase I study with investigational influenza vaccine candidate. |
CureVac (CVAC) Gets a Buy Rating from JMP SecuritiesIn a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on CureVac (CVAC – Research Report), with a price target of $52.00. The company's shares closed last Thursday at $18.64, close to its 52-week low of $16.34. According to TipRanks.com, Buchanan is ranked 0 out of 5 stars with an average return of -13.4% and a 32.7% success rate. Buchanan covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Arbutus Biopharma, and Hookipa Pharma. Currently, the analyst consensus on CureVac is a Hold with an average price target of $36.00, representing a 90.5% upside. |
CureVac starts Phase 1 trial for experimental flu shot developed with GSKShares of CureVac gained 2.6% in premarket trading on Thursday after the company said it began dosing participants in a Phase 1 clinical trial assessing an experimental mRNA-based influenza vaccine it developed with GlaxoSmithKline . The open-label study plans to enroll 240 adults. CureVac had previously tried to develop a COVID-19 vaccine but instead decided last year to scrap those plans and instead focus on developing a second-generation COVID-19 shot with GSK. CureVac''s stock has tumbled 83.7% over the past year, while the broader S&P 500 is up 17.3%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news. |
CVAC Price Returns
| 1-mo | N/A |
| 3-mo | -29.27% |
| 6-mo | -59.57% |
| 1-year | -79.44% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -59.57% |
| 2021 | -57.68% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...